Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Reexamination Certificate
2002-03-14
2010-06-22
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
C424S134100, C424S192100, C424S197110, C530S350000, C530S387300
Reexamination Certificate
active
07740853
ABSTRACT:
The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the FcεRI receptor by a chimeric cytotoxin Fc2′-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40′—a truncated form of PE lacking the cell binding domain. The chimeric protein, produced inE. coli, specifically and efficiently kills mouse mast cell lines expressing the FcεRI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of FcεRI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for FcεRI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product ofPseudomonas aeruginosa. The present invention also relates to a method for the preparation of said protein. This chimeric protein is prepared by genetically fusing the Fc region of the mouse IgE molecule to PE40, a truncated form of PE lacking the cell binding domain. The present invention also provides pharmaceutical compositions, for the treatment of allergic diseases and for the treatment of hyperplasias and malignancies, comprising as an active ingredient the above mentioned chimeric protein and a conventional adjuvant product.
REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4902495 (1990-02-01), Kaliner et al.
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5378688 (1995-01-01), Nett et al.
patent: 5458878 (1995-10-01), Pastan et al.
patent: 5512658 (1996-04-01), Pastan et al.
patent: 5602095 (1997-02-01), Pastan et al.
patent: 5672686 (1997-09-01), Chittenden
patent: 5759782 (1998-06-01), Pastan et al.
patent: 5834234 (1998-11-01), Gallo
patent: 6008042 (1999-12-01), Dixit et al.
patent: 6022960 (2000-02-01), Potter et al.
patent: 6140066 (2000-10-01), Lorberboum-Galski et al.
patent: 6169074 (2001-01-01), Montal et al.
patent: 6172213 (2001-01-01), Lowman et al.
patent: 6218363 (2001-04-01), Baserga et al.
patent: 6645490 (2003-11-01), Yarkoni et al.
patent: 6919079 (2005-07-01), Fishman et al.
patent: 6933271 (2005-08-01), Yarkoni et al.
patent: 2009/0082549 (2009-03-01), Fishman et al.
patent: WO 88/00204 (1988-01-01), None
patent: 9000565 (1990-01-01), None
patent: WO 90/09799 (1990-09-01), None
patent: WO 9012592 (1990-11-01), None
patent: WO 9111456 (1991-08-01), None
patent: WO 93/15751 (1993-08-01), None
patent: WO 9404689 (1994-03-01), None
patent: 9606116 (1996-02-01), None
patent: 9624675 (1996-08-01), None
patent: 9638571 (1996-12-01), None
patent: 9712632 (1997-04-01), None
patent: 9719179 (1997-05-01), None
patent: 9722364 (1997-06-01), None
patent: 9945128 (1999-09-01), None
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Attwood et al, The Babel of Bioinformatics, 2000, Science vol. 290 No. 5491: 471-473.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Nissim et al, EMBO J 10(1): 101-107, 1991.
Nature, vol. 331, Jan. 14, 1988, pp. 180-183, Helm et al, “The mast cell binding site on human immunoglobulin E”.
The Journal of Immunology, vol. 140, No. 8, Apr. 15, 1988, pp. 2585-2588, Kitani et al., “Inhibition of Allergic Reactions with Monoclonal Antibody to the High Affinity IgE Receptor”.
Nature, vol. 339, No. 6223, Jun. 1, 1989, pp. 394-397, Chaudhary V.K. et al., “A recombinant immunotoxin consisting of two antibody variable domains fused to pseudomonas exotoxin”.
The Journal of Biological Chemistry, vol. 263, No. 19, Jul. 5, 1988, pp. 9470-9475, Kondo et al, “Activity of Immunotoxins Constructed With Modified Pseudomonas Exotoxin A Lacking the Cell Recognition Domain”.
Immunopharmacology, vol. 14, pp. 47-62, 1987, Howard Boltansky et al, “IgE-immunotoxins, II. IgE-ricin A-chain”.
Nature, vol. 331, Jan. 14, 1988, pp. 180-183, Helm et al., “The mast cell binding site on human immunoglobulin E”.
The Journal of Immuonology, vol. 140, No. 8, Apr. 15, 1988, pp. 2585-2588, Kitani et al., “Inhibition of Allergic Reactions with Monoclonal Antibody to the High Affinity IgE Receptor”.
Nature, vol. 339, No. 6223, Jun. 1, 1989, pp. 394-297, Chaudhary V. K. et al., “A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to Pseudomonas Exotoxin.”.
Immunopharmacology, vol. 14, pp. 47-62, 1987, Boltansky et al., “IgE-immunotoxins. II. IgE-ricin A-chain”.
Antonsson et al. “Inhibition of Bax channel-forming activity by Bcl-2,” Science vol. 277, 1997, pp. 370-372.
Bailon et al. “Purification and Partial Characterization of an Interleukin 2-Pseudomonas exotoxin Fusion Protein,” Biotechnol. vol. 6, 1988, pp. 1326-1329.
Bargou et al. “Overexpression of the death promoting gene bax a which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice” J. Clin. Invest. vol. 97(11), Jun. 1996, p. 2651.
Becker et al. “Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia” Proc. Natl. Acad. Sci. USA vol. 94, 1997, pp. 10873-10878.
Ben-Yehuda et al., “I.V. Administration of L-GNRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice”, Int J Cancer 92(2):263-268 (2001).
Ben-Yehuda et al., “Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice”, Med Oncol 16(1):38-45 (Apr. 1999).
Beraud et al. “Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40” Cell. Immunol. vol. 133, 1991, pp. 379-789.
Bird et al. “Single-chain antigen-binding proteins” Science vol. 242, 1988, pp. 423-426.
Boise et al. “bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death” Cell vol. 74, 1993, pp. 597-608.
Boyd et al. “Bik, a novel death-inducing protein shares a distinct sequence motif with bcl-2 family proteins and interacts with viral and cellular survival promoting proteins” Oncogene vol. 11, 1995, p. 1921.
Brousset et al. “Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's Disease” Blood vol. 87, 1996,k pp. 2470-2475.
Case et al. “Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats” Proc. Natl. Acad. Sci. USA vol. 86, 1989, pp. 287-291.
Chatterjee et al, “Idiotypic antibody immunotherapy of caner”, Cancer Immunol Immunother 38(2): 75-82 (1994).
Chaudhary et al., “Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin”, Proc Natl Acad Sci USA 84(13):4538-4542 (1987).
Chaudhary et al., “Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity”, J.Biol Chem 265(27): 16306-16310(1990).
Chittenden et al. “Induction of apoptosis by the Bcl-2 homologue Bak” Nature vol. 374, 1995, pp. 733-736.
Chittenden et al. “A Conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions” EMBO J. vol. 14, 1995, pp. 5589-5596.
Cohen “Caspases: the executioners of apoptosis” Biochem J. vol. 326, 1997, pp. 1-16.
Curtis et al. “Enhanced hematopoietic activity of a human granulocyte/macrophage . . . ” Proc. Natl. Acad. Sci. USA vol. 88, 1991, pp. 5809-5813.
Dermer, Biotechnology 12:320 (1994).
Diaz et al. “A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members” J.B.C. vol. 272, 1997, pp. 11350-11355.
Dixon et al. “Apo
Fishman Alla
Lorberboum-Galski Haya
Yarkoni Shai
Huynh Phuong
Volpe and Koenig P.C.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Fcepsilon-pe chimeric protein for targeted treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fcepsilon-pe chimeric protein for targeted treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fcepsilon-pe chimeric protein for targeted treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4238069